Home Cart Sign in  
Chemical Structure| 501-36-0 Chemical Structure| 501-36-0

Structure of Resveratrol
CAS No.: 501-36-0

Chemical Structure| 501-36-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Resveratrol is one of the numerous polyphenolic compounds found in several vegetal sources, has a wide spectrum of targets with IC50 of 0.8, 1, 3.3 and 5 μM for Adenylyl cyclase, IKKβ, DNA polymerase α and δ, respectively.

Synonyms: trans-Resveratrol; SRT501; Vineatrol 20M

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Krueger, Nadine ; Kronenberger, Thales ; Xie, Hang ; Rocha, Cheila ; Poehlmann, Stefan ; Su, Haixia , et al.

Abstract: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has forced the development of direct-acting antiviral drugs due to the coronavirus disease 2019 (COVID-19) pandemic. The main protease of SARS-CoV-2 is a crucial enzyme that breaks down polyproteins synthesized from the viral RNA, making it a validated target for the development of SARS-CoV-2 therapeutics. New chem. phenotypes are frequently discovered in natural goods. In the current study, we used a fluorogenic assay to test a variety of natural products for their ability to inhibit SARS-CoV-2 Mpro. Several compounds were discovered to inhibit Mpro at low micromolar concentrations It was possible to crystallize robinetin together with SARS-CoV-2 Mpro, and the X-ray structure revealed covalent interaction with the protease's catalytic Cys145 site. Selected potent mols. also exhibited antiviral properties without cytotoxicity. Some of these powerful inhibitors might be utilized as lead compounds for future COVID-19 research.

Keywords: COVID-19 ; antivirals ; coronavirus ; covalent drugs ; dynamic light scattering ; inhibitors ; main protease ; natural products

Alternative Products

Product Details of Resveratrol

CAS No. :501-36-0
Formula : C14H12O3
M.W : 228.24
SMILES Code : OC1=CC(/C=C/C2=CC=C(O)C=C2)=CC(O)=C1
Synonyms :
trans-Resveratrol; SRT501; Vineatrol 20M
MDL No. :MFCD00133799
InChI Key :LUKBXSAWLPMMSZ-OWOJBTEDSA-N
Pubchem ID :445154

Safety of Resveratrol

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H319
Precautionary Statements:P305+P351+P338

Related Pathways of Resveratrol

DNA
GPCR
pyroptosis
TLR

Isoform Comparison

Biological Activity

Target
  • SIRT1

  • JNK1

    JNK1, IC50:50 μM

In Vitro:

Cell Line
Concentration Treated Time Description References
Caco-2 cells 1, 5, 25 µM To observe the inhibitory effect of Resveratrol on SR-B1 and NF-κB-p65, results showed that Resveratrol did not repress SR-B1 or NF-κB-p65 expression in Caco-2 cells. PMC10169763
Neonatal mouse cardiomyocytes 10 μM 30 min To investigate the protective effects of resveratrol on OGD/R-induced cardiomyocyte apoptosis. Results showed that resveratrol significantly inhibited OGD/R-induced cell apoptosis and LDH leakage. PMC3916794
ectopic endometrial stroma cells (EcESCs) 25 and 50 µM 12 and 24 h inhibited the proliferation, migration, and invasion of endometrial stromal cells PMC7578554
Ishikawa cells 25 and 50 µM 24 and 48 h inhibited the migration and invasion of Ishikawa cells PMC7578554
H9C2 cells 25 µM 12 h To investigate the ameliorative effect of Resveratrol on autophagic flux under oxidative stress, the results showed that Resveratrol improved autophagic flux and reduced apoptosis in H9C2 cells through a SIRT1-dependent pathway. PMC4190906
SH-SY5Y cells 10 μM 48 h Resveratrol significantly rescued cell survival in OGD-treated SH-SY5Y cells and reduced inflammation and oxidative stress through AMPK signaling. PMC9570351
MCF-7 breast cancer cells 10 μM 7 days To assess the effect of resveratrol on MCF-7 cell proliferation, cells in steroid-depleted media were treated for 7 days with several ER ligands including resveratrol. Unlike E2, resveratrol did not stimulate cell proliferation. PMC4017646
HEK293-T cells 10 μM 24 h To evaluate the interaction of Resveratrol with ERα and coactivators SRC1-3 using a mammalian two-hybrid assay, results showed that Resveratrol induced full association of ERα with SRC2, but reduced interaction with SRC1 or SRC3. PMC4017646
C2C12 myotubes 50 μM, 100 μM 48 h Assess cytotoxicity, results showed that 50 and 100 μM of resveratrol did not exhibit significant cytotoxicity in C2C12 myotubes. PMC7918168
C2C12 myotubes 50 μM, 100 μM 24 h Assess mitochondrial DNA gene expression, results showed that resveratrol significantly increased the expression of mitochondrial DNA genes in C2C12 myotubes. PMC7918168
C2C12 myotubes 50 μM 24 h Assess mitochondrial content, results showed that resveratrol significantly increased the mitochondrial content in C2C12 myotubes. PMC7918168
H460 0-200 μM 24 hours Evaluate the effect of YI-12 on H460 cell viability, showing an IC50 value of 107.9 ± 10.28 μM. PMC11921031
A549 0-200 μM 24 hours Evaluate the effect of YI-12 on A549 cell viability, showing an IC50 value of 96.9 ± 8.95 μM. PMC11921031

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice High-fat diet-induced obesity model Diet 0.5% in diet 8 weeks To study the metabolic effects of Resveratrol in high-fat diet-induced obese mice, results showed that Resveratrol inhibited intestinal SR-B1 expression, reduced chylomicron secretion, and improved lipid metabolism. PMC10169763
Mice Pde6aD670G mutant mice Oral 120 mg/L Starting from postnatal day 0 until the end of the experiment To evaluate the neuroprotective effects of resveratrol on the retina of Pde6aD670G mice. The results showed that resveratrol did not have a significant effect on visual function. PMC7005447
Mice Ischemia/reperfusion injury model Intraperitoneal injection 10 mg/kg Single dose, 60 minutes To investigate the cardioprotective effects of resveratrol on ischemia/reperfusion injury. Results showed that resveratrol significantly reduced myocardial infarct size and decreased serum LDH and CK activity. PMC3916794
nude mice endometriosis model intraperitoneal injection 25 mg/kg daily for 4 weeks inhibited the growth of ectopic endometrium and the expression of MTA1 and ZEB2 PMC7578554
C57BL/6J mice Streptozotocin (STZ)-induced diabetic model Dietary administration 60 mg/kg and 300 mg/kg Once daily for 12 weeks To investigate the protective effect of Resveratrol on cardiac function in diabetic mice, the results showed that Resveratrol improved cardiac function, reduced myocardial hypertrophy and fibrosis, and alleviated oxidative stress and apoptosis by regulating autophagic flux. PMC4190906

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT04689412 Wheezing|Upper Respiratory Tra... More >>ct Infections Less << COMPLETED 2019-04-30 Università di Perugia, Perugia... More >>, 06100, Italy Less <<
NCT00256334 Colon Cancer|Cancer PHASE1 COMPLETED 2025-04-09 Chao Family Comprehensive Canc... More >>er Center, Orange, California, 92868, United States Less <<
NCT01451918 Dyslipidaemia|Insulin Resistan... More >>ce Less << PHASE2 COMPLETED 2025-09-13 Toronto General Hospital, Toro... More >>nto, Ontario, Canada Less <<
NCT01354977 Type 2 Diabetes Mellitus|Insul... More >>in Resistance Less << PHASE2 COMPLETED 2017-09-15 Albert Einstein College of Med... More >>icine, Bronx, New York, 10461, United States Less <<
NCT03933163 Friedreich Ataxia PHASE2 COMPLETED 2024-03-28 Royal North Shore Hospital, St... More >> Leonards, New South Wales, 2065, Australia|University of Queensland Centre for Clinical Research, Herston, Queensland, 4029, Australia|Murdoch Children's Research Institute, Parkville, Victoria, 3052, Australia|Royal Perth Hospital, Perth, Western Australia, 6000, Australia Less <<
NCT03665740 Gulf War Illness PHASE2 UNKNOWN 2022-08-31 VISN 17 Center of Excellence f... More >>or Research on Returning War Veterans, Waco, Texas, 76711, United States Less <<
NCT01339884 Friedreich Ataxia PHASE1|PHASE2 COMPLETED 2025-12-12 Monash Medical Centre, Souther... More >>n Health, Clayton, Melbourne, Victoria, 3168, Australia Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.38mL

0.88mL

0.44mL

21.91mL

4.38mL

2.19mL

43.81mL

8.76mL

4.38mL

References

 

Historical Records

Categories